908 Devices and HJB Announce Joint Innovation Partnership
908 Devices, a pioneer of analytical devices for chemical and biomolecular analysis, announced a joint innovation partnership with Hangzhou Just Biotherapeutics (HJB). HJB is a China based company focused on technologies that accelerate development of biotherapeutics and reduce manufacturing costs to make medicines more readily available in the global marketplace.
908 Devices is a Boston headquartered company. It also announced the availability of their ZipChip platform in China. ZipChip is a plug-and-play separations platform that optimizes mass spectrometry analysis. It is designed to accelerate productivity throughout the drug discovery and development processes.Researchers can be up and running samples in no time. Each chip integrates microfluidic technology to provide high-resolution separations in just three minutes or less and helps researchers to keep pace with rising analytical demands.
HJB has recently launched a world-class pharmaceutical development facility in Hangzhou, Zhejiang where only leading-edge technologies — including the 908 Devices ZipChip® platform — will be integrated into their on-site processes.”We are searching for analytical tools that can provide higher quality data, get us to results faster, and can be leveraged to reduce overall manufacturing costs,” said Dr. Jonathan Zhao, Co-Founder and CEO of HJB. “The ZipChip platform is a prime example as it streamlines internal processes and gives us access to data we haven’t been able to get before. We believe it will be very impactful to our business.”
Dr. Kevin J. Knopp, CEO and Co-Founder of 908 Devices added “HJB is extremely innovative and has a clear vision for how ZipChip can give them the edge they need in all stages of biopharma development and production.We are truly excited about our partnership with HJB and the role 908 Devices can play in their overarching mission to develop vital, accessible medicines.”
Source: 908 Devices